文献速递消化道肿瘤与早癌消化内镜

重复粪便免疫化学检测与乙状结肠镜筛查结直肠癌:随机试验基线结果

Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial.
PubMed 文献 · Gastroenterology · 2020-11-21

挪威东南部50-74岁人群随机接受一次乙状结肠镜或每两年一次FIT筛查,共纳入139291人。FIT组3轮累积参与率68%高于乙状结肠镜组52%;3轮FIT后结直肠癌检出率0.49%高于乙状结肠镜0.27%(OR 1.87),进展期腺瘤检出率2.7% vs 2.4%(OR 1.14);严重不良事件两组相当。

要点

  • 重复FIT筛查的3轮累积参与率68%,高于乙状结肠镜的52%。
  • 3轮FIT后结直肠癌检出率0.49%,高于乙状结肠镜的0.27%。
  • 两组严重不良事件发生率分别为0.05%和0.07%,差异无统计学意义。

核心结论

  • 与一次乙状结肠镜相比,重复FIT筛查参与率更高,且检出更多结直肠癌和进展期腺瘤。
  • 两组穿孔和出血风险相当。

研究设计与样本

  • 随机试验,2012至2019年邀请挪威东南部50-74岁个体,随机分入一次柔性乙状结肠镜组或每两年一次FIT筛查组。
  • 共纳入139291人,乙状结肠镜组69195人,FIT组70096人。
  • 本报告数据来自两组完全招募后,包括2轮完整FIT和部分第3轮FIT。

主要发现

  • 参与率:乙状结肠镜组52%,FIT第1轮58%,FIT 3轮累积68%。
  • 结直肠癌检出率:FIT第1轮0.25% vs 乙状结肠镜0.27%(OR 0.92;95%CI 0.75-1.13);FIT 3轮累积0.49% vs 0.27%(OR 1.87;95%CI 1.54-2.27)。
  • 进展期腺瘤检出率:FIT第1轮1.4% vs 乙状结肠镜2.4%(OR 0.57;95%CI 0.53-0.62);FIT 3轮累积2.7% vs 2.4%(OR 1.14;95%CI 1.05-1.23)。

关键数值与推荐

  • 乙状结肠镜后推荐结肠镜的条件:发现≥10mm息肉、≥3个腺瘤、任何进展期腺瘤或结直肠癌。
  • FIT阳性推荐结肠镜的阈值:粪便血红蛋白>15μg/g。

临床怎么用

  • 重复FIT筛查可作为结直肠癌筛查策略,参与率和肿瘤检出率均较高。
  • 乙状结肠镜与FIT的严重不良事件风险相当,选择时需综合考虑参与率和检出获益。

局限性

  • 本报告为基线结果,包括2轮完整FIT和部分第3轮FIT,长期结局尚未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The comparative effectiveness of sigmoidoscopy and fecal immunochemical testing (FIT) for colorectal cancer (CRC) screening is unknown. METHODS: Individuals aged 50-74 years living in Southeast Norway were randomly invited between 2012 and 2019 to either once-only flexible sigmoidoscopy or FIT screening every second year. Colonoscopy was recommended after sigmoidoscopy if any polyp of ≥10 mm, ≥3 adenomas, any advanced adenomas, or CRC was found or, subsequent to, FIT >15 μg hemoglobin/g feces. Data for this report were obtained after complete recruitment in both groups and included 2 full FIT rounds and part of the third round. Outcome measures were participation, neoplasia detection, and adverse events. Age-standardized detection rates and age-adjusted odds ratios (ORs) were calculated. RESULTS: We included 139,291 individuals: 69,195 randomized to sigmoidoscopy and 70,096 to FIT. The participation rate was 52% for sigmoidoscopy, 58% in the first FIT round, and 68% for 3 cumulative FIT rounds. Compared to sigmoidoscopy, the detection rate for CRC was similar in the first FIT round (0.25% vs 0.27%; OR, 0.92; 95% confidence interval [CI], 0.75-1.13) but higher after 3 FIT rounds (0.49% vs 0.27%; OR, 1.87; 95% CI, 1.54-2.27). Advanced adenoma detection rate was lower in the first FIT round compared to sigmoidoscopy at 1.4% vs 2.4% (OR, 0.57; 95% CI, 0.53-0.62) but higher after 3 cumulative FIT rounds at 2.7% vs 2.4% (OR, 1.14; 95% CI, 1.05-1.23). There were 33 (0.05%) serious adverse events in the sigmoidoscopy group compared to 47 (0.07%) in the FIT group (P = .13). CONCLUSIONS: Participation was higher and more CRC and advanced adenomas were detected with repeated FIT compared to sigmoidoscopy. The risk of perforation and bleeding was comparable. Clinicaltrials.gov, Number: NCT01538550.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Randel KR, Schult AL, Botteri E, et al. Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial. Gastroenterology. 2020. PMID: 33227280. doi:10.1053/j.gastro.2020.11.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。